Publications by authors named "K Halaburda"
Article Synopsis
- A study analyzed outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for favorable risk Acute Myeloid Leukemia (AML) patients in complete remission across three time periods, involving 1850 patients.
- Over the years from 2015 to 2021, older patients (≥60 years) and those with NPM1FLT3 diagnoses increased, while Haploidentical transplants also grew significantly.
- The study found a reduction in chronic graft-versus-host disease and improved GVHD-free, relapse-free survival for patients transplanted after 2010 compared to earlier periods, though other outcomes showed no significant changes during the study period.
Allogeneic haematopoietic cell transplantation (allo-HCT) remains an option for tyrosine kinase inhibitor-resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high-risk patients with advanced disease phases. In this European Society for Blood and Marrow Transplantation (EBMT) registry-based study of 1686 CML patients undergoing first allo-HCT between 2012 and 2019, outcomes were evaluated according to donor type, particularly focusing on mismatched related donors (MMRDs). Median age at allo-HCT was 46 years (IQR 36-55).
View Article and Find Full Text PDFOutcomes following allogeneic hematopoietic cell transplantation (allo-HCT) for chronic myeloid leukemia (CML) with post-transplantation cyclophosphamide (PTCy) using an unrelated donor (UD) or a mismatched related donor (MMRD) remain unknown. We report a retrospective comparison of PTCy-based allo-HCT from a UD, non-PTCy allo-HCT from a UD, and PTCy allo-HCT from an MMRD. Inclusion criteria were adult patients with CML undergoing first allo-HCT between 2012 and 2019 from a UD with either PTCy or non-PTCy graft-versus-host disease (GVHD) prophylaxis or from an MMRD using PTCy.
View Article and Find Full Text PDFAllogeneic hematopoietic cell transplantation (allo-HCT) is curative for myelofibrosis (MF) but assessing risk-benefit in individual patients is challenging. This complexity is amplified in CALR-mutated MF patients, as they live longer with conventional treatments compared to other molecular subtypes. We analyzed outcomes of 346 CALR-mutated MF patients who underwent allo-HCT in 123 EBMT centers between 2005 and 2019.
View Article and Find Full Text PDFArticle Synopsis
- * The cumulative incidence of VOD/SOS was low, with 1.8% at day 21 and 2.4% at day 100, indicating that most patients developed classical VOD/SOS with several risk factors present.
- * Treatment with defibrotide led to resolution in 58% of patients, with better outcomes seen in those with moderate severity